Enanta Pharmaceuticals, Inc. (ENTA)

$51.51

+0.02 (+0.04%)
Rating:
Recommendation:
Buy
Symbol ENTA
Price $51.51
Beta 0.355
Volume Avg. 0.17M
Market Cap 1.076B
Shares () -
52 Week Range 37.59-79.495
1y Target Est -
DCF Unlevered ENTA DCF ->
DCF Levered ENTA LDCF ->
ROE -34.73% Strong Sell
ROA -32.43% Strong Sell
Operating Margin -
Debt / Equity 16.83% Neutral
P/E -
P/B 3.30 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ENTA news


Dr. Jay Luly
Healthcare
Biotechnology
NASDAQ Global Select

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.